
|Articles|October 1, 2003
Vision outcomes create optimistic expectation for spectacle independence
Author(s)Cheryl Guttman
Editor's Note: The CrystaLens was recommended for approval by the FDA's Ophthalmic Devices Advisory Panel in late May. The lens may be commercially available later this year or early 2004. Dr. Doane's presentation was given at the annual meeting of the American Society of Cataract and Refractive Surgery prior to the recommendation.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Innovations in glaucoma poised for breakthrough in 2026 (and what might hold them back)
2
STAAR Surgical terminates proposed acquisition by Alcon
3
FDA Clears IND application for GenEditBio’s GEB-101 in TGFBI corneal dystrophy
4
Rates of retinal layer thinning predict visual field progression in glaucoma
5












































